Department of Neurosurgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
Charité CyberKnife Center, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
Radiat Oncol. 2020 May 22;15(1):115. doi: 10.1186/s13014-020-01535-1.
Stereotactic radiosurgery (SRS) is an effective treatment for trigeminal neuralgia (TN). Nevertheless, a proportion of patients will experience recurrence and treatment-related sensory disturbances. In order to evaluate the predictors of efficacy and safety of image-guided non-isocentric radiosurgery, we analyzed the impact of trigeminal nerve volume and the nerve dose/volume relationship, together with relevant clinical characteristics.
Two-hundred and ninety-six procedures were performed on 262 patients at three centers. In 17 patients the TN was secondary to multiple sclerosis (MS). Trigeminal pain and sensory disturbances were classified according to the Barrow Neurological Institute (BNI) scale. Pain-free-intervals were investigated using Kaplan Meier analyses. Univariate and multivariate Cox regression analyses were performed to identify predictors.
The median follow-up period was 38 months, median maximal dose 72.4 Gy, median target nerve volume 25 mm, and median prescription dose 60 Gy. Pain control rate (BNI I-III) at 6, 12, 24, 36, 48, and 60 months were 96.8, 90.9, 84.2, 81.4, 74.2, and 71.2%, respectively. Overall, 18% of patients developed sensory disturbances. Patients with volume ≥ 30 mm were more likely to maintain pain relief (p = 0.031), and low integral dose (< 1.4 mJ) tended to be associated with more pain recurrence than intermediate (1.4-2.7 mJ) or high integral dose (> 2.7 mJ; low vs. intermediate: log-rank test, χ = 5.02, p = 0.019; low vs. high: log-rank test, χ = 6.026, p = 0.014). MS, integral dose, and mean dose were the factors associated with pain recurrence, while re-irradiation and MS were predictors for sensory disturbance in the multivariate analysis.
The dose to nerve volume ratio is predictive of pain recurrence in TN, and re-irradiation has a major impact on the development of sensory disturbances after non-isocentric SRS. Interestingly, the integral dose may differ significantly in treatments using apparently similar dose and volume constraints.
立体定向放射外科(SRS)是治疗三叉神经痛(TN)的有效方法。然而,一部分患者会经历复发和与治疗相关的感觉障碍。为了评估图像引导非等中心放射外科治疗的疗效和安全性的预测因素,我们分析了三叉神经体积和神经剂量/体积关系以及相关临床特征的影响。
在三个中心对 262 名患者进行了 296 次治疗。在 17 名患者中,TN 继发于多发性硬化症(MS)。根据巴罗神经研究所(BNI)量表对三叉神经痛和感觉障碍进行分类。使用 Kaplan-Meier 分析研究无疼痛间隔。进行单变量和多变量 Cox 回归分析以确定预测因素。
中位随访时间为 38 个月,最大剂量中位数为 72.4Gy,靶神经体积中位数为 25mm,处方剂量中位数为 60Gy。6、12、24、36、48 和 60 个月时疼痛控制率(BNI I-III)分别为 96.8%、90.9%、84.2%、81.4%、74.2%和 71.2%。总体而言,18%的患者出现感觉障碍。体积≥30mm 的患者更有可能保持疼痛缓解(p=0.031),而低积分剂量(<1.4mJ)比中积分剂量(1.4-2.7mJ)或高积分剂量(>2.7mJ)更有可能导致疼痛复发(低 vs. 中:对数秩检验,χ²=5.02,p=0.019;低 vs. 高:对数秩检验,χ²=6.026,p=0.014)。MS、积分剂量和平均剂量是疼痛复发的相关因素,而再次放疗和 MS 是多变量分析中感觉障碍的预测因素。
神经体积剂量比是预测 TN 疼痛复发的因素,而非等中心 SRS 后再放疗对感觉障碍的发展有重大影响。有趣的是,在使用明显相似的剂量和体积限制的治疗中,积分剂量可能有很大差异。